Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 9:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,795 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Group Clear all

Conditions: Posttraumatic Stress Disorder
Interventions: Group Based Exposure Therapy, Present Centered Group Therapy; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: Male only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Decatur, Georgia

Conditions: Hypertension
Interventions: Pharmacists Only (Control Group), Combined Intervention (Pharmacists + CHW Interventions); Other
Lead sponsor: Texas Southern University; Other
Eligibility: 55 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity
Interventions: CAAT: Appetite Awareness, CRST: Volcravo, Combined CAAT and CRST program; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 8 Years to 12 Years
Enrollment: 236 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Erectile Dysfunction
Interventions: Nitric Oxide, Tadalafil, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: RHA Investments Ltd; Industry
Eligibility: 40 Years to 65 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Pressure Injury
Interventions: Mepilex Border Flex® (MBF) dressing; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Brain Injury
Interventions: Polypharmacy using FDA-approved products, Median Nerve Stimulation (MNS), Nutraceutical Supplementation, Standard of Care; Drug · Device · Dietary Supplement + 1 more
Lead sponsor: International Brain Research Foundation; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Edison, New Jersey

Conditions: Multiple Myeloma
Interventions: Lenalidomide, Dexamethasone, Elranatamab; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions: HealthPROMISE users, Control Group; Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Opioid-use Disorder
Interventions: BupreCare, Buprenorphine/naloxone, MEMS; Device · Drug · Other
Lead sponsor: MedicaSafe, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 2
States / cities: San Diego, California • Baltimore, Maryland

Conditions: Pediatric Hemiparesis
Interventions: Transcranial Direct Current Stimulation (tDCS), Placebo Comparator; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 8 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Conditions: Hepatitis B, Hepatitis C, Liver Disease
Interventions: Video Doctor, PA + PPN; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 431 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: San Francisco, California

Conditions: Rubella, Measles, Mumps
Interventions: Priorix, M-M-R II, Varivax, Havrix, Prevnar 13; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Months to 15 Months
Enrollment: 5,016 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 62
States / cities: Dothan, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 56 more

Conditions: Aging, Aging Well, Healthy Aging
Interventions: Nitrate enriched beetroot juice, Nitrate depleted beetroot juice, 12 week of combined exercise training; Dietary Supplement · Other
Lead sponsor: Florida Institute for Human and Machine Cognition; Other
Eligibility: 60 Years and older
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Pensacola, Florida

Conditions: Aggression
Interventions: PATHS to PAX, PATHS to PAX and the Incredible Years; Behavioral
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 5 Years and older
Enrollment: 5,233 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Mal de Débarquement Syndrome
Interventions: VOR Readaptation, VOR Habituation, Visual Motion Desensitization, Opposing visual motion stimulus; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 78 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Kidney Transplantation
Interventions: CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more

Conditions: Food Selection, Nutrition, Food Preferences, Dietary Habits, Sustainability, Healthy Diet
Interventions: Health swaps, Climate swaps, Combined health and climate swaps, Control; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 1,201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Hypertension
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Acute Myeloid Leukemia
Interventions: Venetoclax, Gemtuzumab, Ziftomenib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 3 Years to 21 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Tobacco Use
Interventions: e-cigarette, Nicotine patch, Nicotine lozenge; Behavioral · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab, Placebo, Permitted DMARDs; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 156
States / cities: Birmingham, Alabama • Montgomery, Alabama • Lake Havasu City, Arizona + 135 more

Conditions: HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Group 2 Pulmonary Hypertension
Interventions: JK07; Drug
Lead sponsor: Salubris Biotherapeutics Inc; Industry
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Fluid Loss, Dialysis
Interventions: CM-1500; Device
Lead sponsor: Zynex Monitoring Solutions; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cardiovascular Diseases
Interventions: Cardiac rehabilitation - high intensity interval training (HIIT), Cardiac rehabilitation - moderate intensity continuous training (MICT), Cardiac rehabilitation - control, Cardiac rehabilitation - observational; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Group Based Exposure Therapy for Combat-Related PTSD

The "Check, Monitor, Control Hypertension" Study is a 24-month Randomized Trial in Houston Targeting African Americans Aged 55+. It Combines Pharmacist Counseling and CHW Support to Improve Blood Pressure Control in Hypertension Management.

A Study to Determine the Effectiveness of a Self-regulation Program to Treat Pediatric Obesity

The Effects of a Nitrate Supplementation on Erectile Function

Decreasing Intraoperative Skin Damage in Prone Position Surgeries

A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness

ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)

Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life

Improving Office Based Treatment of Opioid Use Disorder With Technology

Brain Stimulation and Hand Training in Children With Hemiparesis

Patient-Centered Care and Asian Americans

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults

An Evaluation of an Integrated Approach to Prevention and Early Intervention in the Elementary School Years

DevRobust Treatment for Mal de Débarquement Syndrome

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

Food Swaps to Improve the Healthfulness and Reduce the Carbon Footprint of Grocery Purchases

A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Quit or Switch: E-cigarette Study

A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis

Study of JK07 in Patients With Heart Failure and WHO Group 2 Combined Post- and Pre-Capillary Pulmonary Hypertension

Clinical Evaluation of the CM-1500 During Hemodialysis

Cardiac Rehab and Cerebral Blood Flow Study